Fachpublikationen

2.Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. Köhler J, Schuler M, Gauler TC, Nöpel-Dünnebacke S, Ahrens M, Hoffmann AC, Kasper S, Nensa F, Gomez B, Hahnemann M, Breitenbuecher F, Cheufou D, Özkan F, Darwiche K, Hoiczyk M, Reis H, Welter S, Eberhardt WE, Eisenacher M, Teschler H, Stamatis G, Schmiegel W, Hahn SA, Baraniskin A.
J Cancer Res Clin Oncol. 2015 Dec 19. [Epub ahead of print]
 

3.Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. Christoph Pöttgen, Martin Stuschke, Britta Graupner, Dirk Theegarten, Thomas Gauler, Verena Jendrossek, Lutz Freitag, Jehad Abu Jawad, Eleni Gkika, Jeremias Wohlschlaeger, Stefan Welter, Matthias Hoiczyk, Martin Schuler, Georgios Stamatis and Wilfried Eberhardt, BMC Cancer. 2015; 15: 363. Published online 2015 May 6
 

4.Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC).J Thorac Oncol. 2015 Jan;10(1):156-63.
 

5.Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium. Oncologist. 2014 Oct;19(10):1100-9.
 

6.Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. Eur J Surg Oncol. 2014 Apr;40(4):412-9.
 

7.Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Bauer S, Hilger RA, Mühlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, Reichardt A, Ahrens M, Reichardt P, Grunewald S, Scheulen ME, Pustowka A, Bock E, Schuler M, Pink D. Br J Cancer. 2014 Mar 4;110(5):1155-62.
 

8.Eberhardt W.E.E., Hoiczyk M, Christoph DC Übersicht: Therapie des Lungenkarzinoms Thieme Tumor Diagnostik und Therapie 12/2013 Schwerpunkt: Lungentumore
 

9.Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina E, Hoiczyk M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F. Ann Surg Oncol. 2013 Sep;20(9):2937-43. 
 

10.Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age. Hoiczyk M, Grabellus F, Podleska L, Ahrens M, Schwindenhammer B, Taeger G, Pöttgen C, Schuler M, Bauer S. Int J Oncol. 2013 Jul;43(1):23-8.
 

11.Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR. J Thorac Oncol. 2013 Jan;8(1):19-30.
 

12.Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. Grabellus F, Podleska LE, Sheu SY, Bauer S, Pöttgen C, Kloeters C, Hoiczyk M, Lauenstein TC, Schmid KW, Taeger G. Eur J Surg Oncol. 2013 Jan;39(1):61-7.
 

13.Intimal sarcoma of the pulmonary artery with unusual findings: a case report. Hoiczyk M, Iliodromitis K, Bauer S, Konorza T, Philipp S, Bankfalvi A, Gerl JM, Schuler M, Erbel R. Clin Res Cardiol. 2012 May;101(5):397-401.
 

14.Gastrointestinale Stromatumoren-Epidemiologie, Ätiologie und Prognose Hoiczyk M Thieme Tumor Diagnostik und Therapie 10/2010
 

15.Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours. Bauer S, Mühlenberg T, Leahy M, Hoiczyk M, Gauler T, Schuler M, Looijenga L. Eur Urol. 2010 Apr;57(4):679-87.
 

16.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR. Eur J Haematol. 2005 Jan;74(1):40-6.

17.Referententätigkeit:

• DGK Herbsttagung 2009 Dresden: Erfolgreiche Lysetherapie bei Sondenthrombus
   
• DGK Herbsttagung 2009 Dresden: 76-jährige Patientin mit unklarer Thrombose der rechten Pulmonalarterie
   
• DGHO 2011 Basel: Trabectedin in soft-tissue sarcoma
   
• ASCO 2012 Chicago: Rechallenge with ifosfamide-containing regimen as salvage option for patients with metastatic soft tissue sarcoma
   
• DGHO 2013 Wien: Zerebrale Metastasierung bei Sarkompatienten- Inzidenz, Prognose und klinisches Ergebnis
   
• ASCO 2014 Chicago: Brain metastases in sarcoma patients